drugset / Trial / NCT07204418
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
NaParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2026-12-03
- Completion
- 2026-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xanomeline | Small molecule | — | — |
| Background | Trospium | Small molecule | — | — |
Indications
No indication recorded.